Business context and reporting period
Inovio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing DNA immunotherapies and vaccines with electroporation delivery technology for cancer and infectious diseases. This unaudited Form 10-Q covers the three months ended March 31, 2015; comparisons are with Q1 2014. The company had no approved human products and no product-sales revenue.
Financial metrics
| Metric | Q1 2015 | Q1 2014 / comparison |
|---|---|---|
| Revenue | $5.17 million | $2.36 million; up 119% |
| Research and development expense | $9.43 million | $8.23 million |
| General and administrative expense | $4.11 million | $4.13 million |
| Operating loss | $8.37 million | $10.00 million |
| Net loss attributable to Inovio | $10.58 million; $0.17 basic and $0.18 diluted loss per share | $10.82 million; $0.20 loss per share |
| Net cash used in operating activities | $12.07 million | $5.56 million |
| Cash and cash equivalents | $26.15 million | $40.54 million at Dec. 31, 2014 |
| Short-term investments | $54.87 million | $53.08 million at Dec. 31, 2014 |
| Working capital | $79.2 million | $84.9 million at Dec. 31, 2014 |
| Total assets / liabilities | $117.86 million / $14.43 million | $131.79 million / $20.25 million at Dec. 31, 2014 |
Cash plus short-term investments totaled approximately $81.0 million at quarter-end. The filing reports no borrowings; liabilities included deferred revenue, accrued expenses, warrant liabilities and deferred rent. Operating margin was approximately negative 162% of revenue, based on reported figures.
Material changes versus the prior comparable period
- Revenue increased mainly because $3.0 million of previously deferred Roche revenue was recognized following Roche’s partial termination of the collaboration in February 2015.
- R&D expense rose about $1.2 million, primarily from increased employee headcount and clinical-trial inventory; G&A expense was broadly flat.
- Operating loss narrowed, but net loss improvement was modest; the quarter included a $2.35 million loss from the GeneOne investment, compared with $0.38 million in Q1 2014.
- Operating cash use more than doubled year over year, and quarter-end cash and investments fell from $93.6 million at year-end 2014 to $81.0 million.
- No financing cash was raised in Q1 2015, compared with $69.9 million in Q1 2014.
Outlook, commentary, risks and unusual items
- Management expected substantial losses to continue as the company funded research, clinical trials and regulatory work. It stated that cash and investments were expected to meet planned working-capital requirements through the end of 2018; this is management’s estimate, not a guarantee.
- On May 5, 2015, after quarter-end, Inovio completed a public offering of 10.925 million shares at $8.00 per share, generating approximately $81.9 million in net proceeds. This materially increased funding but diluted existing shareholders.
- Roche returned rights to prostate-cancer candidate INO-5150 after terminating that part of the agreement; the hepatitis B collaboration for INO-1800 continued. Potential event-based payments under the original agreement were reduced significantly.
- Key risks include clinical and regulatory failure or delays, manufacturing and funding needs, dependence on collaborators and grants, competition, and the possibility that the company may never commercialize products or become profitable.
- The company reported $13.62 million in future minimum operating-lease payments. It reported no material litigation and stated disclosure controls were effective at March 31, 2015.
Important facts for investors to verify
- Whether clinical milestones and trial results support continued development across the pipeline, particularly after Roche’s return of INO-5150 rights.
- Whether the stated cash runway through 2018 remains reasonable given operating cash use, planned R&D spending and the post-quarter offering proceeds.
- The terms and dilution effects of the May 2015 share offering and the company’s future financing needs.
- The drivers and valuation sensitivity of the GeneOne investment loss and the company’s related-party balances and arrangements.
- Whether collaboration, grant and government-contract revenue remains available and diversified; Q1 revenue included a material one-time Roche deferred-revenue release.